Scarica l'app Stockscreener
14.94
6.16%
-0.98
Dopo l'orario di chiusura:
14.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$15.92
Aprire:
$16.24
Volume 24 ore:
1.71M
Relative Volume:
1.24
Capitalizzazione di mercato:
$1.74B
Reddito:
$674.41M
Utile/perdita netta:
$-173.05M
Rapporto P/E:
-9.7373
EPS:
-1.5343
Flusso di cassa netto:
$-48.07M
1 W Prestazione:
-5.68%
1M Prestazione:
-16.21%
6M Prestazione:
+41.61%
1 anno Prestazione:
+6.33%
Intervallo 1D:
$14.91
$16.24
Intervallo di 1 settimana:
$14.91
$16.44
Portata 52W:
$9.82
$21.45
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.94 | 1.84B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Novocure Receives Approval In Japan For Optune Pax For The Treatment Of Unresectable Locally Advanced Pancreatic Cancer - marketscreener.com
Japan approves a wearable device to use with chemo for advanced pancreatic cancer. - Stock Titan
A results call is set for 8 a.m. Oct. 29, when Novocure will discuss third-quarter results. - Stock Titan
Price to earnings forward of NovoCure Ltd. – HAN:038 - TradingView
ETFs Investing in NovoCure Ltd. Stocks - TradingView
Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus - Simply Wall Street
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us
NovoCure stock reports 15.6 percent Q2 revenue growth - AD HOC NEWS
NovoCure Limited (NVCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change? - simplywall.st
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall - Yahoo Finance Singapore
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change - Yahoo Finance Singapore
Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR) - simplywall.st
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even - TradingView
Is It Too Late to Buy NovoCure Ltd (NVCR) After 3.1% Rally? GF V - GuruFocus
Novocure at Morgan Stanley conference: growth, discipline and expansion By Investing.com - Investing.com India
NovoCure Limited at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Novocure at Morgan Stanley conference: growth, discipline and expansion - Investing.com
NovoCure (NVCR) Stock Looks Cheap On Sales But Weak On Adoption Risk - simplywall.st
NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026 - kalkinemedia.com
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com South Africa
NovoCure at Wells Fargo healthcare conference: launch momentum builds - Investing.com
Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026 - marketscreener.com
Timothy Scannell retires from NovoCure board, seat vacated Sept 2, 2026 - TradingView
NovoCure (NASDAQ: NVCR) director steps down with no dispute - Stock Titan
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Yahoo Finance
NOVOCURE LTD (NVCR) Stock Chart - ChartMill
Novocure Ltd (NVCR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cash flow from operating activities of NovoCure Ltd. – HAM:038 - TradingView
Net debt of NovoCure Ltd. – HAM:038 - TradingView
NovoCure says cyberattack caused patient data exposure - Yahoo Finance
Basic earnings per share (basic EPS) of NovoCure Ltd. – HAM:038 - TradingView
NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk - simplywall.st
NewsNovocure discloses cyberattack exposing records of more than 1,400 US cancer patients - teiss
Novocure Announces Upcoming Investor Events - finance.yahoo.com
NovoCure (NASDAQ: NVCR) Data Breach Exposes IDs Linked to Over 1,400 U.S. Patient Records - Kalkine Media
Novocure Reveals Major Breach of Cancer Patient Records - sqmagazine.co.uk
Oncology firm Novocure says cyberattack exposed US patient records - CNA
NVCR Looks 3.4% Undervalued on GF Value™ Amid Cybersecurity Inci - GuruFocus
Novocure reports data access affecting patient IDs for 1,400+ U.S. records; no device access - TradingView
NovoCure cyber breach hits 1,400+ patient records - Stock Titan
Novocure Ltd (NVCR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Novocure Ltd (NVCR) Peer Comparison – Compare with Others - Value Research
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates? - simplywall.st
NovoCure Limited (NVCR) Stock Price & News - Syfe
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors? - simplywall.st
A Look at NovoCure Ltd (NVCR) After 3.7% Decline -- GF Value $18 - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Down 4%What's Next? - MarketBeat
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice - Yahoo Finance
Novocure | 8-K: Current report - Moomoo
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novocure Ltd Azioni (NVCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):